Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

Arthritis Research & Therapy

Rocio Caño¹  Silvia Gómez¹  Mercedes Freire²  Paloma Vela³  Lourdes Mateo⁴  Cristina Bohorquez⁵  María C. Castro-Villegas⁶  Cesar Díaz-Torné⁷  Inmaculada Ros-Vilamajo⁸  Juan M. Blanco-Madrigal⁹  Juan J. Gómez-Reino^1,10  Carolina Perez-Garcia^1,11  Fernando Sánchez-Alonso^1,12  Carlos Sanchez-Piedra^1,12  Federico Díaz-González^1,12 

[1] ISABIAL;Rheumatology, Hospital A Coruña;Rheumatology, Hospital General Universitario Alicante;Rheumatology, Hospital Germans Trias i Pujol;Rheumatology, Hospital Príncipe de Asturias;Rheumatology, Hospital Reina Sofía;Rheumatology, Hospital Santa Creu i Sant Pau;Rheumatology, Hospital Son Llatzer;Rheumatology, Hospital de Basurto;Rheumatology, Hospital de Santiago;Rheumatology, Hospital del Mar;Unidad de Investigación SER;

关键词: Rheumatoid arthritis;    Ankylosing spondylitis;    Psoriatic arthritis;    Biologics;    Elderly-onset rheumatoid arthritis;   

DOI  :  10.1186/s13075-020-02231-x

来源: DOAJ

【 摘 要 】

Abstract Objectives To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). Methods All patients in the BIOBADASER registry diagnosed with RA, AS, and PsA, and classified as young (< 25 years old), adult (25–64 years old), elderly (65–75 years old) or very elderly (> 75 years old) at start of biological treatment were included. Factors associated with the appearance of a first AE using adjusted incidence rate ratios (IRR) (Poisson regression) were analyzed. Survival to first AE was studied by Kaplan-Meier analysis and hazard ratios (HR) by Cox regression. Results 2483 patients were included: 1126 RA, 680 PsA, and 677 AS. Age group stratification was as follows: 63 young, 2127 adults, 237 elderly, and 56 very elderly. Regression model revealed an increased probability of suffering a first AE at age 65 years or older [IRR elderly: 1.42 (CI95% 1.13–1.77)]. Other characteristics associated with AE were female gender, the use of DMARDs, including methotrexate, the presence of comorbidities, and the time of disease duration. Factors that had the greatest impact on survival over a first AE were age > 75 years [HR 1.50 (1.01–2.24)] and female gender [HR 1.42 (1.22–1.64)]. Conclusion Age at the start of treatment and female gender are key factors associated with the appearance of a first AE with biologics. Other factors related to patient status and treatment were also associated with a first AE in rheumatic patients treated with biologics.

【 授权许可】

Unknown